HUP0101189A2 - Vas-dextrán vegyület felhasználása vashiány megelőzésére és kezelésére szolgáló gyógyszerkészítmény alkotórészeként, eljárás a nevezett vas-dextrán vegyület előállítására, és a nevezett vegyület felhasználása parenterálisan beadható gyógyszerkészítmény... - Google Patents

Vas-dextrán vegyület felhasználása vashiány megelőzésére és kezelésére szolgáló gyógyszerkészítmény alkotórészeként, eljárás a nevezett vas-dextrán vegyület előállítására, és a nevezett vegyület felhasználása parenterálisan beadható gyógyszerkészítmény...

Info

Publication number
HUP0101189A2
HUP0101189A2 HU0101189A HUP0101189A HUP0101189A2 HU P0101189 A2 HUP0101189 A2 HU P0101189A2 HU 0101189 A HU0101189 A HU 0101189A HU P0101189 A HUP0101189 A HU P0101189A HU P0101189 A2 HUP0101189 A2 HU P0101189A2
Authority
HU
Hungary
Prior art keywords
iron
dextran
daltons
compound
molecular weight
Prior art date
Application number
HU0101189A
Other languages
English (en)
Inventor
Hans Berg Andreasen
Lars Christensen
Original Assignee
Pharmacosmos Holding A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8093321&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0101189(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding A/S filed Critical Pharmacosmos Holding A/S
Publication of HUP0101189A2 publication Critical patent/HUP0101189A2/hu
Publication of HUP0101189A3 publication Critical patent/HUP0101189A3/hu
Publication of HU228483B1 publication Critical patent/HU228483B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

A találmány tárgya ember és állat vashiányának megelőzésére vagykezelésére szolgáló, parenterálisan bevihető gyógyszerkészítménybenkomponensként alkalmazott vas-dextrán vegyület. A találmány lényege,hogy olyan molekulatömegű hidrogénezett dextránt tartalmaz, melynektömegátlaga (Mw) 700-1400 Dalton, előnyösen 1000 Dalton körüli,számátlaga (Mn) 400-1000 Dalton, a dextrán tömegének 90 %-ában amolekulatömeg 2700 Dalton alatti, a legmagasabb molekulatömegű 10tömeg% dextránfrakció tömegátlaga (Mw) 3200 Dalton alatti érték, és anevezett hidrogénezett dextrán membrán-eljárással - melynekleválasztási értéke 340 és 800 Dalton közötti - tisztított, stabilasszociációt biztosítva a vas(III)-oxi-hidroxiddal. A vegyületelőállításánál membrános eljárást alkalmaznak, hogy eltávolítsák a2700 Daltonnál nagyobb és a 340-800 Dalton molekulatömegűhidrogénezett dextránfrakciókat, szacharidokat, mielőtt a vas(III)-hidroxidot a dextrán jelenlétében kicsapják, amit hőkezelés éstisztítás követ. Ó
HU0101189A 1998-03-25 1999-03-24 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition HU228483B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK199800420A DK172860B1 (da) 1998-03-25 1998-03-25 Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
PCT/DK1999/000160 WO1999048533A1 (en) 1998-03-25 1999-03-24 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition

Publications (3)

Publication Number Publication Date
HUP0101189A2 true HUP0101189A2 (hu) 2001-08-28
HUP0101189A3 HUP0101189A3 (en) 2003-12-29
HU228483B1 HU228483B1 (en) 2013-03-28

Family

ID=8093321

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0101189A HU228483B1 (en) 1998-03-25 1999-03-24 An iron-dextran compound for use as a component in a therapeutical composition for prophylaxis or treatment of iron-deficiency, a process for producing said iron-dextran compound and use of said compound for the preparation of a parenterally administrable therapeutical composition

Country Status (28)

Country Link
US (1) US6291440B1 (hu)
EP (1) EP1066056B2 (hu)
JP (1) JP4558198B2 (hu)
KR (1) KR100612071B1 (hu)
CN (1) CN1147322C (hu)
AR (1) AR015738A1 (hu)
AT (1) ATE220560T1 (hu)
AU (1) AU740432B2 (hu)
BR (1) BRPI9908914B8 (hu)
CA (1) CA2322633C (hu)
CZ (1) CZ300823B6 (hu)
DE (1) DE69902154T3 (hu)
DK (2) DK172860B1 (hu)
EA (1) EA003427B1 (hu)
ES (1) ES2180279T5 (hu)
HK (1) HK1033426A1 (hu)
HU (1) HU228483B1 (hu)
ID (1) ID26778A (hu)
NO (1) NO329591B1 (hu)
NZ (1) NZ505983A (hu)
PL (1) PL195582B1 (hu)
PT (1) PT1066056E (hu)
SI (1) SI1066056T2 (hu)
SK (1) SK284499B6 (hu)
TR (1) TR200002733T2 (hu)
UA (1) UA70939C2 (hu)
WO (1) WO1999048533A1 (hu)
ZA (1) ZA200004016B (hu)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977249B1 (en) 1998-11-20 2005-12-20 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
DE60043188D1 (de) * 1999-04-09 2009-12-03 Amag Pharmaceuticals Inc Hitzebeständige umhüllte kolloidale eisenoxide
KR20020003344A (ko) * 2001-12-17 2002-01-12 유형선 철분 보급제 경구 투여 제제 조성물
BR0308773A (pt) * 2002-04-09 2005-02-09 Pharmacosmos Holding As Compostos de dextrina de ferro para tratamento de anemia por deficiência de ferro
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) * 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
DE102004031181A1 (de) * 2004-06-28 2006-01-19 Vifor (International) Ag Phosphatadsorbens
ITMO20050056A1 (it) * 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
EP2626074A1 (en) 2006-01-06 2013-08-14 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
EP1947120A1 (de) * 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
EP1997833A1 (de) * 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
CN101585887B (zh) * 2008-05-22 2011-12-14 中国科学院过程工程研究所 应用纳滤技术对右旋糖酐铁络合物水溶液进行脱盐和浓缩的方法
EP3156075B1 (en) 2009-03-25 2020-10-14 Pharmacosmos Holding A/S An oligosaccharide and a process for preparation thereof
CN101967205B (zh) * 2010-10-12 2013-04-17 滨州学院 一种β-葡聚糖铁复合物及其制备方法
EP2537866A1 (en) 2011-06-21 2012-12-26 Serumwerk Bernburg AG Hydroxyethyl starch derivatives, method for manufacturing the same and therapeutical uses thereof
PL398814A1 (pl) 2012-04-16 2013-10-28 Uniwersytet Jagiellonski Zastosowanie pochodnych dekstranu do przeciwdzialania lub leczenia niedokrwistosci
US10172882B2 (en) 2014-06-22 2019-01-08 Dexcel Pharma Technologies Ltd. Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
HUE045092T2 (hu) * 2014-10-27 2019-12-30 Pharmacosmos Holding As Vérszegénység kezelése vagy megelõzése vemhes nem-humán emlõsökben és utódaikban
JP7426927B2 (ja) 2017-09-11 2024-02-02 ファーマコスモス ホールディング エー／エス 治療的使用のための鉄錯体化合
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
CN110183548B (zh) * 2019-06-28 2021-05-18 瑞普（天津）生物药业有限公司 一种低分子葡聚糖铁的制备方法及其应用
BR112024002150A2 (pt) 2021-08-03 2024-04-30 Pharmacosmos Holding As Compostos de complexo de ferro para uso subcutâneo na terapia de deficiência de ferro em animais de companhia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24642E (en) 1959-04-28 Therapeutic preparations of iron
DK117730A (hu)
US2885393A (en) 1956-02-24 1959-05-05 R K Laros Company Dextran-iron complex and process for making same
US3093545A (en) 1960-08-29 1963-06-11 Armour Pharma Therapeutic iron-dextran preparations
US3234209A (en) * 1963-09-13 1966-02-08 Chemicals Inc Process for making iron hydrogenated dextran
DE1293144B (de) * 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
GB1183940A (en) 1966-10-22 1970-03-11 Fisons Pharmaceuticals Ltd Ferric Hydroxide Complexes
GB1200902A (en) 1967-05-13 1970-08-05 Fisons Pharmaceuticals Ltd Iron-dextran complexes
CH507993A (de) 1967-07-13 1971-05-31 Kutnowskie Zakl Farma Verfahren zur Herstellung von Eisen(III)-komplexverbindungen mit hydriertem Dextran
DK129353B (da) 1968-04-29 1974-09-30 Fisons Pharmaceuticals Ltd Analogifremgangsmåde til fremstilling af et ferrihydroxid-dextranderivatkompleks eller en opløsning deraf.
US3697502A (en) 1969-11-03 1972-10-10 Christensen Henry M Method of making iron dextran-preparations
GB1562913A (en) * 1976-06-16 1980-03-19 Fisons Ltd Fractionating fluid mixtures of dextrans
DE3422249A1 (de) * 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5102652A (en) * 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
IT1263831B (it) * 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
RU2093577C1 (ru) * 1993-11-04 1997-10-20 Государственный институт кровезаменителей и медицинских препаратов Способ получения декстрана
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
US5624668A (en) * 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977249B1 (en) 1998-11-20 2005-12-20 Pharmacosmos Holding A/S Process for producing an iron-dextran compound, iron-dextran compound produced according to said process, pharmaceutical composition for prophylaxis or treatment of iron-deficiency and use of said compound for the preparation of parenterally administrable pharmaceutical composition

Also Published As

Publication number Publication date
BRPI9908914B1 (pt) 2012-06-12
NO20004151D0 (no) 2000-08-18
NO329591B1 (no) 2010-11-15
DE69902154D1 (de) 2002-08-22
BRPI9908914A (pt) 2000-11-21
US6291440B1 (en) 2001-09-18
SI1066056T2 (sl) 2009-04-30
ATE220560T1 (de) 2002-08-15
EA003427B1 (ru) 2003-04-24
DK1066056T4 (da) 2009-04-14
CA2322633A1 (en) 1999-09-30
UA70939C2 (uk) 2004-11-15
ES2180279T5 (es) 2009-05-05
EA200000981A1 (ru) 2001-02-26
EP1066056A1 (en) 2001-01-10
SI1066056T1 (en) 2002-12-31
NO20004151L (no) 2000-08-18
PL343164A1 (en) 2001-07-30
ES2180279T3 (es) 2003-02-01
DK172860B1 (da) 1999-08-16
SK14092000A3 (sk) 2001-04-09
CN1147322C (zh) 2004-04-28
DK1066056T3 (da) 2002-10-14
AU2827399A (en) 1999-10-18
KR100612071B1 (ko) 2006-08-11
EP1066056B2 (en) 2008-12-10
HK1033426A1 (en) 2001-08-31
CA2322633C (en) 2009-01-27
AR015738A1 (es) 2001-05-16
ID26778A (id) 2001-02-08
ZA200004016B (en) 2001-07-25
JP4558198B2 (ja) 2010-10-06
CN1293577A (zh) 2001-05-02
SK284499B6 (sk) 2005-05-05
PT1066056E (pt) 2002-12-31
DK42099A (da) 1999-08-16
DE69902154T2 (de) 2003-03-06
NZ505983A (en) 2002-11-26
WO1999048533A1 (en) 1999-09-30
KR20010034641A (ko) 2001-04-25
CZ300823B6 (cs) 2009-08-19
JP2002507582A (ja) 2002-03-12
HUP0101189A3 (en) 2003-12-29
TR200002733T2 (tr) 2000-12-21
AU740432B2 (en) 2001-11-01
DE69902154T3 (de) 2009-07-09
EP1066056B1 (en) 2002-07-17
CZ20003535A3 (cs) 2001-04-11
PL195582B1 (pl) 2007-10-31
HU228483B1 (en) 2013-03-28
BRPI9908914B8 (pt) 2021-07-06

Similar Documents

Publication Publication Date Title
HUP0101189A2 (hu) Vas-dextrán vegyület felhasználása vashiány megelőzésére és kezelésére szolgáló gyógyszerkészítmény alkotórészeként, eljárás a nevezett vas-dextrán vegyület előállítására, és a nevezett vegyület felhasználása parenterálisan beadható gyógyszerkészítmény...
DE69428122D1 (de) Phosphatbindende polymere für orale verabreichung
WO2003047524A3 (en) Methods and compositions for modulating the immune system and uses thereof
EP2305269A3 (en) Immunemodulating oligosaccharides
WO1997025052A3 (en) Compositions comprising pvp having an average molecular weight in the range of 3,000 to 14,000 daltons
DE69915458D1 (de) Dextran formulierungen zur behandlung entzündlicher gelenkerkrankungen
MXPA04006039A (es) Metodo para el tratamiento de afecciones vasculares y neuronales perifericas.
BR0112962A (pt) Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
NZ333925A (en) Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
CA2527365A1 (en) Compositions for prevention and treatment of cold and influenza-like symptoms comprising chelated zinc
TR200002078T2 (tr) Sentetik polisakkaridler, hazırlanmaları için proses ve bunları içeren farmasötik kompozisyonlar.
EP2060255A3 (en) Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
PT1181024E (pt) Utilizacao de glicosaminoglicanos para o tratamento da demencia senil
WO2003049667A3 (en) The method of treating cancer
DE60214889D1 (en) Sucroseoctasulphat silber saltz
HK1084023A1 (en) Glycosaminoglycans for treating emotional dysfunctions
EP1095658A3 (en) Use of ribose to treat fibromyalgia
EP0948338B1 (en) Utilization of an egg-based preparation as an antidepressant
ES2165792A1 (es) "oligomeros de bloque conteniendo grupos 1-hidrocarbiloxi-2,2,6,6-tetrametil-4-piperidilo como estabilizadores para materiales organicos"
현정애 et al. Two Cases of Fordyce Granules
CA2242618A1 (en) Compositions comprising ultrapure pvp having an average molecular weight in the range of 7,000 to 12,000 daltons
JO2370B1 (en) Pharmaceutical formulations for the treatment of painful, inflamed and ulcerated conditions of wet epithelial surfaces such as mucositis, stomatitis and Behçet syndrome
WO2000029433A3 (en) 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines